These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 32409605)
21. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Zhang N; Wu X; Yang L; Xiao F; Zhang H; Zhou A; Huang Z; Huang S Clin Cancer Res; 2012 Nov; 18(21):5961-71. PubMed ID: 22977194 [TBL] [Abstract][Full Text] [Related]
22. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214 [TBL] [Abstract][Full Text] [Related]
23. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
24. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782 [TBL] [Abstract][Full Text] [Related]
25. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair. Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938 [TBL] [Abstract][Full Text] [Related]
26. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype. Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385 [TBL] [Abstract][Full Text] [Related]
27. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412 [TBL] [Abstract][Full Text] [Related]
28. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. Kim JS; Shin DH; Kim JS J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480 [TBL] [Abstract][Full Text] [Related]
29. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. Liu B; Zhou J; Wang C; Chi Y; Wei Q; Fu Z; Lian C; Huang Q; Liao C; Yang Z; Zeng H; Xu N; Guo H Cell Death Dis; 2020 May; 11(5):384. PubMed ID: 32439916 [TBL] [Abstract][Full Text] [Related]
30. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399 [TBL] [Abstract][Full Text] [Related]
31. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells. Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458 [TBL] [Abstract][Full Text] [Related]
32. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment. Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175 [TBL] [Abstract][Full Text] [Related]
33. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. Wang S; Chen C; Li J; Xu X; Chen W; Li F J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273 [TBL] [Abstract][Full Text] [Related]
34. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181 [TBL] [Abstract][Full Text] [Related]
35. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Wang HH; Chang TY; Lin WC; Wei KC; Shin JW Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714 [TBL] [Abstract][Full Text] [Related]
36. Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel. Ngo MT; Harley BAC Biomaterials; 2019 Apr; 198():122-134. PubMed ID: 29941152 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
38. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896 [TBL] [Abstract][Full Text] [Related]
39. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897 [TBL] [Abstract][Full Text] [Related]
40. Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. Anderson JC; Duarte CW; Welaya K; Rohrbach TD; Bredel M; Yang ES; Choradia NV; Thottassery JV; Yancey Gillespie G; Bonner JA; Willey CD Radiother Oncol; 2014 Jun; 111(3):468-74. PubMed ID: 24813092 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]